• O G Rewa, S M Bagshaw, X Wang, R Wald, O Smith, J Shapiro, B McMahon, K D Liu, S A Trevino, L S Chawla, and J L Koyner.
• Department of Critical Care Medicine, University of Alberta, Edmonton, AB, Canada. Electronic address: rewa@ualberta.ca.
• J Crit Care. 2019 Aug 1; 52: 109-114.

PurposeTo validate the furosemide stress test (FST) for predicting the progression of acute kidney injury (AKI).Materials And MethodsWe performed a multicenter, prospective, observational study in patients with stage I or II AKI. The FST (1 mg/kg for loop diuretic naïve patients and 1.5 mg/kg in patients previously exposed to loop diuretics) was administered. Subsequent urinary flow rate (UFR) recorded and predictive ability of urinary output was measured by the area under the curve receiver operatic characteristics (AuROC). Primary outcome was progression to Stage III AKI. Secondary outcomes included in-hospital mortality and adverse events.ResultsWe studied 92 critically ill patients. 23 patients progressed to stage III AKI and had significantly lower UFR (p < 0.0001). The UFR during the first 2 h was most predictive of progression to stage III AKI (AuROC = 0.87), with an ideal cut-off of less than 200mls, with a sensitivity of 73.9% and specificity of 90.0%.ConclusionIn ICU patients without severe CKD with mild AKI, a UFR of less than 200mls in the first 2 h after an FST is predictive of progression to stage III AKI. Future studies should focus on incorporating a FST as part of a clinical decision tool for further management of critically ill patients with AKI.Copyright © 2019 Elsevier Inc. All rights reserved.

24 keywords...

hide…